BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cell News » Press Releases

OrganaBio Initiates GMP Manufacturing Operations at its New Cell Therapy Manufacturing Facility

June 24, 2022 By Cade Hildreth (CEO) Leave a Comment

OrganaBio CDMO
  • With the commencement of GMP manufacturing operations, OrganaBio’s CDMO offers the cell therapy industry ready access to flexible manufacturing solutions and clinical grade cellular raw materials.
  • OrganaBio, a cell therapy CDMO, expands manufacturing with ISO 7 cleanrooms for 3rd party manufacturing and GMP cellular starting material production.

[Read more…]

Filed Under: Cell Therapy, Press Releases

Axol Bioscience Announces CiPA-Validated Human iPSC-Derived Ventricular Cardiomyocytes

June 24, 2022 By Cade Hildreth (CEO) Leave a Comment

Axol Bioscience
Axol Bioscience’s CiPA-validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool.

June 7, CAMBRIDGE, England & EDINBURGH, Scotland – Axol Bioscience Ltd., an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening. [Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cell News

Defined Bioscience to Develop Stem Cells and iPSC-derived Tissue for Life Science and Cultivated Meat Applications

June 21, 2022 By Cade Hildreth (CEO) Leave a Comment

Defined Bioscience
Defined Bioscience Announces Formation of Its Scientific Advisory Board

San Diego, CA, June 15, 2022 — Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Defined Bioscience team on the development and commercialization of cell culture reagents, growth medium and kits to consistently grow high quality stem cells and iPSC-derived tissue with applications in life science and cultivated meat. [Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cells

A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting

June 14, 2022 By Cade Hildreth (CEO) Leave a Comment

i-peaces-cell-manufacturing

Palo Alto, California, June 14, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously. There are various automated cell processing/expansion systems in the market today, but this is the first high-throughput, automated cell processing system that is capable of inducing iPSCs from somatic cells. [Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cell News, Stem Cells

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

June 10, 2022 By Cade Hildreth (CEO) Leave a Comment

Umoja Bipharma and Treefrog Therapeutics
Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.

[Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cells

  • 1
  • 2
  • 3
  • …
  • 66
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.